Publication: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
No Thumbnail Available
Identifiers
Date
2018-09-25
Authors
Paz-Ares, Luis
Luft, Alexander
Vicente, David
Tafreshi, Ali
Gümüş, Mahmut
Mazières, Julien
Hermes, Barbara
Çay Şenler, Filiz
Csőszi, Tibor
Fülöp, Andrea
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Non-Small-Cell Lung
Double-Blind Method
Female
Humans
Intention to Treat Analysis
Lung Neoplasms
Male
Middle Aged
Paclitaxel
Programmed Cell Death 1 Receptor
Progression-Free Survival
Survival Analysis
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Non-Small-Cell Lung
Double-Blind Method
Female
Humans
Intention to Treat Analysis
Lung Neoplasms
Male
Middle Aged
Paclitaxel
Programmed Cell Death 1 Receptor
Progression-Free Survival
Survival Analysis